Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have received an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $29.2857.

ZVRA has been the subject of several recent research reports. Maxim Group lifted their price target on Zevra Therapeutics from $25.00 to $35.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Citizens Jmp increased their price objective on Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “market outperform” rating in a report on Tuesday, June 9th. Cantor Fitzgerald raised their target price on Zevra Therapeutics from $24.00 to $34.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Guggenheim lifted their target price on Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, June 10th. Finally, Weiss Ratings cut Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research report on Friday, May 22nd.

Zevra Therapeutics Trading Down 24.0%

ZVRA opened at $9.52 on Friday. Zevra Therapeutics has a 12 month low of $7.16 and a 12 month high of $15.03. The company has a market cap of $562.82 million, a PE ratio of 4.78 and a beta of 0.85. The company has a 50 day moving average of $12.37 and a 200 day moving average of $10.46.

Zevra Therapeutics (NASDAQ:ZVRA) last issued its earnings results on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.12. The business had revenue of $36.22 million for the quarter, compared to analysts’ expectations of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. Research analysts forecast that Zevra Therapeutics will post 0.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Zevra Therapeutics

Several hedge funds have recently bought and sold shares of the company. AIGH Capital Management LLC bought a new stake in Zevra Therapeutics during the 1st quarter worth approximately $11,184,000. Marshall Wace LLP bought a new position in Zevra Therapeutics in the 3rd quarter valued at $8,676,000. Rubric Capital Management LP boosted its holdings in Zevra Therapeutics by 60.8% in the 2nd quarter. Rubric Capital Management LP now owns 1,958,318 shares of the company’s stock valued at $17,253,000 after purchasing an additional 740,584 shares during the period. Adage Capital Partners GP L.L.C. boosted its holdings in Zevra Therapeutics by 15.2% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,168,000 shares of the company’s stock valued at $36,720,000 after purchasing an additional 550,000 shares during the period. Finally, Nantahala Capital Management LLC grew its position in shares of Zevra Therapeutics by 34.0% during the 3rd quarter. Nantahala Capital Management LLC now owns 1,971,936 shares of the company’s stock valued at $18,753,000 after purchasing an additional 500,000 shares in the last quarter. Hedge funds and other institutional investors own 35.03% of the company’s stock.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.